David E. Lazar - 22 Dec 2025 Form 3 Insider Report for Indaptus Therapeutics, Inc. (INDP)

Reporting relationship: Co-Chief Executive Officer
Issuer ticker: INDP
Reported as of: 22 Dec 2025
Net transaction value: $0
SEC form: 3
Accepted by SEC: 23 Dec 2025, 19:06:26 UTC
Prior SEC filing: 22 Dec 2025
Next SEC filing: 05 Jan 2026
Source filing: View source filing
Reporting owner signature: /s/ David E. Lazar

Key filing fact

David E. Lazar filed Form 3 for Indaptus Therapeutics, Inc. (INDP) on 23 Dec 2025.

Key facts

This page summarizes David E. Lazar's Form 3 filing for Indaptus Therapeutics, Inc. (INDP).
0 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 23 Dec 2025, 19:06.

Change

Previous filing in this sequence was filed on 22 Dec 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Official SEC source

Ownership activity is grounded in SEC Form 3 disclosures.

View source filing

Reporting Owners (1)

CIK 0001932843 Primary reporting owner

Lazar David E.

Relationship: Co-Chief Executive Officer
Address: 44, TOWER 100, THE TOWERS WINSTON, CHURCHILL, PAITILLA, PANAMA CITY, PANAMA
Signature: /s/ David E. Lazar
Signature date: 23 Dec 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

INDP holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 0
Date: 22 Dec 2025
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

INDP holding Derivative

Series AA Convertible Preferred Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 22 Dec 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 6,000,000
Exercise price
Footnotes: F2, F3, F4

INDP holding Derivative

Series AAA Convertible Preferred Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 22 Dec 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 105,000,000
Exercise price
Footnotes: F2, F3, F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

No shares of Common Stock are beneficially owned.

Footnote F2

On December 22, 2025, David E. Lazar (the "Reporting Person") and Indaptus Therapeutics, Inc. (the "Company"), entered into a securities purchase agreement pursuant to which the Reporting Person acquired (i) an aggregate of 300,000 shares of the Company's Series AA Convertible Preferred Stock (the "Series AA Preferred Stock") at a price of $6.00 per share and (ii) an aggregate of 700,000 shares of the Company's Series AAA Convertible Preferred Stock (the "Series AAA Preferred Stock", and together with the Series AA Preferred Stock, the "Preferred Stock") at a price of $6.00 per share. Each share of Series AA Preferred Stock is convertible into 20 shares of the Company's Common Stock at any time, subject to certain ownership limitations. Each share of Series AAA Preferred Stock is convertible into 150 shares of the Company's Common Stock at any time, subject to certain ownership limitations.

Footnote F3

The Preferred Stock is perpetual and therefore has no expiration date.

Footnote F4

The shares of Preferred Stock are convertible at the option of the Reporting Person for no additional consideration

SEC remarks

No securities are beneficially owned.